AJ101 is a topical cream formulation being developed for the treatment of acne vulgaris. The active ingredient in AJ101 is a novel androgen receptor degradation enhancer that effectively decreased the level of androgen receptor (AR). In addition, AJ101 displayed anti-inflammatory/antioxidant properties and reduced the expression of extracellular matrix (ECM) proteins in fibroblasts. Results from our global Phase 1 and 2 studies in patients with acne demonstrated that AJ101 was well-tolerated while significantly reduced the inflammatory acne lesion counts and clinical severity. Patients treated with AJ101 showed a higher response rate as defined by Investigator Global Assessment compared to placebo controls. Current efforts are directed to confirm the efficacy of AJ101 in large-scale pivotal clinical studies and to explore potential indications in other androgen and AR-related skin disorders.